CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 885 enrolled
Drug / intervention
Azilsartan medoxomil +2 moredrug
Likely dose
Azilsartan medoxomil 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00760214
NCT00760214Phase 3Completed
CompareCT.gov

A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension

Takeda·interventional·Posted Sep 26, 2008·Updated Nov 15, 2012

In Brief

A Phase 3 clinical trial evaluating Azilsartan medoxomil and Ramipril for Hypertension. Completed, enrolled 885 participants across 72 sites in 10 countries.

Detailed Summary

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to ramipril for treating Essential Hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesBulgaria, Estonia, Finland, Germany, Netherlands, Poland, Russia, Serbia, Slovakia, Sweden
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 26, 2008
Enrollment StartJan 1, 2008
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.8 years ago

Interventions

Azilsartan medoxomildrug

Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.

Azilsartan medoxomildrug

Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.

Ramiprildrug

Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.